Atherton, California

9 Yrs Experience | Live Trade Alerts | Volume Breakouts | Multi-Day Movers | Trend Flips | Day & Swing Trader | Strategy + Learning | Personal Opinions Only

[Atherton, California @AYAISHIDA]

$ARQT advanced after positive clinical update. Dermatology drug progress attracted biotech sector capital inflows

[Atherton, California @AYAISHIDA]

$AROC looks promising today. Natural gas infrastructure business benefits from stable gas price, capital inflow expected. #Trading

[Atherton, California @AYAISHIDA]

ARM saw positive price action on Sep15. AI chip ecosystem optimism fueled buying interest. #TechStocks

[Atherton, California @AYAISHIDA]

CRM has positive catalysts today. New AI customer platform launches, analysts lift revenue forecasts. Improving subscription retention lifts margin expectations. #SaaS

[Atherton, California @AYAISHIDA]

AMD moved up yesterday. New AI chip product launch boosted market sentiment. The company continues to grab market share in data center GPU segment. #AIStock

[Atherton, California @AYAISHIDA]

FTFT surges sharply after completing its 1-for-4 reverse split to meet Nasdaq listing rules. The reduced float attracts heavy retail momentum buying. Watch volume closely, as low-float stocks can reverse rapidly. #FTFT #MicroCap

[Atherton, California @AYAISHIDA]

$NFLX is showing relative strength amid ad-tier subscriber growth and live sports expansion. The stock is consolidating above its 20-day moving average; watch for a volume breakout to confirm the next upward move. #NFLX #Streaming

[Atherton, California @AYAISHIDA]

MSFT steady performance yesterday. AI cloud revenue remains the core driver. Is MSFT still a safe large-cap pick? #MSFT #Cloud

[Atherton, California @AYAISHIDA]

🚨 Robinhood's 24-hour trading sparks market discussion. 24-hour trading: Increased opportunities? Or increased noise? The relationship between platforms, market makers, and retail investors is being redefined.

$HOOD

[Atherton, California @AYAISHIDA]

$ONDS
is taking center stage at the American Drone Leadership Summit on July 31 in Washington, D.C. 🇺🇸 With CEO Eric Brock joining government and defense leaders, the spotlight on U.S. drone technology keeps getting brighter. 📷

[Atherton, California @AYAISHIDA]

🚨
$ONDS

WATCH 📷 Reverse split talks are heating up. A major move for the company as it tries to improve share structure and market visibility. 📷 🔥

[Atherton, California @AYAISHIDA]

$NVDA
🚀 AI scaling requires one thing: MORE MEMORY. NVIDIA’s future GPUs are pushing HBM capacity higher and higher. Rubin Ultra could bring 1TB+ HBM. The AI infrastructure race is only getting started.

[Atherton, California @AYAISHIDA]

📊
$BYND

Fund Signal! Institutional holdings are rising rapidly, indicating increased market participation. Low-priced stocks are attracting more attention. 📷<🚀

[Atherton, California @AYAISHIDA]

$ASTS

| AST SpaceMobile - Down 55% from ATH - Expecting to 5x revenue over the next year - Massive contracts already locked in

[Atherton, California @AYAISHIDA]

$ADBE
revenue is at a record $6.62B, while its P/E has fallen sharply from historical highs. Valuation looks increasingly attractive.

[Atherton, California @AYAISHIDA]

$KEEL

remains an active name on the tape. Turnover has stayed elevated over the past several sessions, with daily readings consistently above 25%. Strong participation often means volatility and opportunity go hand in hand. Keeping this one on the watchlist. 👀

[Atherton, California @AYAISHIDA]

$RKLB

signed another three-launch Electron deal with iQPS marking their third multi-launch agreement in less than a year. The latest booking brings iQPS to 18 total launches with the new missions beginning in late 2027.

[Atherton, California @AYAISHIDA]

$CRWV
CoreWeave signs multi-year agreement with Solidigm

[Atherton, California @AYAISHIDA]

$BMNR
has short term gamma KING magnets at $17, but it has long term gamma KING magnets at $20 a few weeks from now. Stay strong. The time is coming. Watching closely, don't miss out.

[Atherton, California @AYAISHIDA]

$OTLK
After a decade-long wait, LYTENAVA has been approved as the first and only FDA-approved intravitreal bevacizumab formulation for treating wet age-related macular degeneration.